INTRODUCTION TO

1
INTRODUCTION TO JUBILANT FULLY INTEGRATED
SOLUTIONS IN GENERICS
2
Jubilant fact sheet

• Incorporated in 1978 and headquartered in New
  Delhi - India
• Ownership of the company 52 with founders, 30
  with PE and institutions and 18 with public
• Over 25 years of experience in Chemical
  Knowledge-based industry
• Strong Financials Net sales of 416 million in
  FY 2007, PAT of 52 million
• Employs 4,466 people including about 1,050 in RD
• Subsidiaries in Europe (Jubilant Europe), USA
  China
• Global positions in key products, exported to
  over 120 countries

3
Jubilant Pharmaceuticals fact sheet

• Incorporated in 1993
• Based in Gent Belgium
• Subsidiary of Jubilant Life Sciences since 2004
• Broad-spectrum services and products provider to
  pharmaceutical marketing companies in Europe
• Knowledge-based company with excellent track
  record in national MAs, MRPs and DCP procedures

4
Moving up the Pharmaceutical Value Chain
5
Core business

• Jubilant Pharmaceuticals is a totally backward
  integrated service and
• product provider for generic pharmaceutical
  companies.
• Our core business and competences are
• Out-licensing with supply of fully in-house
  developed generics.
• Manufacturing site transfers with production at
  the in-house facility.
• Regulatory Services
• Clinical research at the in-house facility in
  Delhi, India.

6
Backward integration
OUT-LICENSING
RA
SUPPLY
Perfect synergism from API development up to
supply of the finished dosage form, guaranteeing
reliability in quality and timing.
7
Benefits of backward integration
OUT-LICENSING

• strong RD and manufacturing capacities at
  Jubilant India
• Jubilant Pharmaceuticals as the single contact
  point in Europe for licensing, registration and
  supply
• Qualitative supply of dosage form products
• Competitive pricing throughout the entire
  supply term

8
Jubilants facilities

• API In-house API formulation production
• RD Formulation
• Plain dosage forms
• Added-value
• Controlled and sustained release
• BE studies In-house Clinical center
• In-house Regulatory Affairs expertise
• In-house production of pharmaceutical
• dosage forms
• In-house GDP logistics with GMP certification
  
• EU release

9
Jubilant Life Sciences API

• Jubilant develops a range of
• APIs and intermediates in therapeutic
• categories of the central nervous
• system, cardiovascular system, gastro-
• intestinal and anti-infectives.
• These APIs are the core of
• the finished dosage form developments.
• Commercially available molecules with DMF/
• CoS include
• Carbamazepine, Oxcarbazepine, Citalopram,
• Lamotrigine, Risperidone, Tramadol,
• Esomeprazole, Losartan, Pantoprazole,
• Olanzapine...

10
Jubilant Clinsys Clinical Research

• Wholly owned subsidiaries based in Delhi, India
  and Philadelphia, US
• Bioavailability, bioequivalence, pharmacokinetic
  and phase 1 clinical studies
• 46 bed facility spread in 35,000 sq. ft. area in
  Delhi certified by DCGI-India, Bfarm (DE) and
  MEB (NL)
• Own Bio-analytical, PK, Clinical Lab, Statistical
  and quality assurance under one roof
• Clinical research started in June 2005

11
RD Formulation Center

• The development work on dosage forms has a
  therapeutic focus on
• Central Nervous System
• Cardiovascular System
• Anti-infective
• Respiratory System
• Anti-diabetic treatment
• A dedicated team of more than 100 scientists is
  working in laboratories equipped with the latest
  scientific instruments.

12
Dosage form manufacturing

• Jubilant owns a finished dosage forms c-GMP
  compliant manufacturing facility at Roorkee,
  India.
• The facility was set up in July 2007 and EU-GMP
  approved by the UK-MHRA in record time.
• Current annual production capacity is 1.2 billion
  tablets and 330 million capsules with expansion
  foreseen in the near future.
• Production capabilities span
• across various IR, NDDS and taste
• masked oral solids through
• wet and dry granulation
• direct compression
• encapsulation
• spheronisation
• extrusion

13
Jubilants strengths
Quality Reliability

• Complete project management in-house
• Availability of large number of qualified experts
• Strict adherence to EU/US FDA guidelines
• High quality Drug Master Files and CoS

• Highly qualified and experienced scientists
• Novel, patented and non-infringing technologies

Skill / Technologies
Providing integrated offers for licensing and
supply of finished dosage forms to clients in
Europe
One stop solution
Cost
Significant cost saving through full integration
14
Main Focus

• Jubilant understands the outsourcing requirements
  of its customers and transforms their needs into
  solutions.
• Long-term supply of finished dosage forms
  following either
• OUT-LICENSING
• OR
• TURNKEY
• MANUFACTURING
• SITE TRANSFERS

15
One stop solution

• Our customers are companies which
• market sell medicinal products
• are eager to expand their product
  portfolio/geographic territory and want to be
  first to the market
• wish to upgrade to state-of-the-art active
  substances and finished dosage form manufacturing
• prefer to concentrate their resources on
  marketing and choose Jubilant as one stop
  solution for research, development, RA and supply.